This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals
by Zacks Equity Research
AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VONV
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO
Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VYM
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues
by Zacks Equity Research
Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.
Should iShares S&P 500 Value ETF (IVE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVE
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRW
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
J&J (JNJ) Updates COVID Jab Label to Include Blood Clot Risk
by Zacks Equity Research
J&J's (JNJ) decision to update the label of its COVID-19 vaccine came on the heels of the FDA's decision to limit the authorized use of its vaccine due to the risk of TTS.
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Should Vanguard S&P 500 Value ETF (VOOV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOOV
Should Invesco S&P 500 Low Volatility ETF (SPLV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPLV
Is iShares Core S&P U.S. Value ETF (IUSV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IUSV
Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MGV
Should Oshares U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OUSA
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.
AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica
by Zacks Equity Research
AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
by Zacks Equity Research
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QUS